Food and Drug Administration v. Alliance for Hippocratic Medicine, No. 23-235 [Arg: 3.26.2024]
QUESTION PRESENTED:
- Whether respondents have Article III standing to challenge the Food and Drug Administration’s 2016 and 2021 actions with respect to mifepristone’s approved conditions of use;
- whether the FDA’s 2016 and 2021 actions were arbitrary and capricious; and
- whether the district court properly granted preliminary relief.
![Food and Drug Administration v. Alliance for Hippocratic Medicine, No. 23-235 [Arg: 3.26.2024]](https://img.transistor.fm/-W7wJuXtrCNjalP8eeoVbMcMDPdBD15L8CZyJpH0id4/rs:fill:800:800:1/q:60/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lcGlz/b2RlLzE4MDc3Mzcv/MTcxMTQ2MzAxMi1h/cnR3b3JrLmpwZw.webp)